Phaseline

Targets › GFAP

GFAP (Glial fibrillary acidic protein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Jul 2034.

GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. (UniProt, P14136)

Open in Phaseline: the race on GFAP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ionis Pharmaceuticalszilganersen (ION373)
Antisense oligonucleotide targeting GFAP mRNA
GFAPPhase 3Alexander DiseaseJul 2034

Conditions

Alexander Disease (1)

Modalities

other (1)

Companies

Ionis Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.